Skip to main content

Table 2 The summary of clinical trials MSC application in the treatment of PD

From: The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment

Action and target cell

Investigators

Year and location

Estimated enrollment

Purpose

Status

Trial phase

Clinical Trials ID

Intravenous administration of autologous bone marrow derived MSCs

Yang Xiao

Li Li

2011

Guangzhou General Hospital of Guangzhou Military Command

20

Safety and efficacy

Unknown

Phase 1/2

NCT01446614

Intra-arterial administration of autologous bone marrow derived MSCs in progressive supranuclear palsy

Rosaria Giordano

2012

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

25

Safety and efficacy

Unknown

Phase 1/2

NCT01824121

Intra-arterial and intravenous administration of autologous adipose-derived SVF cells

Sharon McQuillan

2014

Ageless Regenerative Institute

0

Safety and efficacy

Recruiting participants

Not Applicable

NCT01453803

Autologous adipose-derived SVF cells. Route of administration not defined

StemGenex

2014

StemGenex San Diego

75

Safety and efficacy

Unknown

 

NCT02184546

Intravenous administration of allogeneic bone marrow-derived MSCs

Mya Schiess

2017

The University of Texas Health Science Center, Houston

20

Safety, feasibility, and efficacy

Recruitment completed

Phase 1

NCT02611167

Intravenous administration of Umbilical Cord Derived MSCs

Xiqing Chai

2018

Hebei Newtherapy BIo-Pharma Technology Co., Ltd

20

Safety and efficacy

Enrolling by invitation

Phase 1

NCT03550183

Intrathecal and Intravenous administration of umbilical cord derived MSCs

Abdallah Awidi

2018

University of Jordan

10

Short term and long term safety

Recruiting

Phase 1/2

NCT03684122

Infusion of allogeneic bone marrow-derived MSCs

Mya C Schiess

2020

The University of Texas Health Science Center, Houston

45

Safety and efficacy

Not yet recruiting

Phase 2

NCT04506073